Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OV329 evaluation in adults with epilepsy and photoparoxysmal response
2026-527114-23-00Phase 2Authorised
- Sponsor
- Ovid Therapeutics
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2 trial of OV329 in epilepsy (2 arms), sponsored by Ovid Therapeutics. Primary endpoint: Change from baseline in standardized photosensitivity range. Planned start Aug 2026; status: authorised.
02
Drugs
OV329
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2026-527114-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527114-23-00.